Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02993523 · ClinicalTrials.gov registry record · Phase 3
A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy
A Phase 3 study of Acute Myeloid Leukemia (AML), sponsored by AbbVie.
- Active
- Registry status
- Phase 3
- Development phase
- 443
- Enrollment target
- 20
- Study locations
NCT02993523: Active Phase 3 study of Acute Myeloid Leukemia (AML), sponsored by AbbVie.
NCT02993523 is a Phase 3 study of Acute Myeloid Leukemia (AML) that is active but no longer recruiting, run by AbbVie. The registered enrollment target is 443 participants, above the 130-participant average among 29 other Acute Myeloid Leukemia (AML) trials with a reported enrollment target (241% higher). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02993523, a Phase 3 study of Acute Myeloid Leukemia (AML), is active but no longer recruiting, sponsored by AbbVie.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 443 participants
- Enrollment target
- 20
- Study locations
Study Summary
Acute Myeloid Leukaemia (AML) is an aggressive and rare cancer of myeloid cells (a white blood cell responsible for fighting infections). Successful treatment of AML is dependent on what subtype of AML the participant has, and the age of the participant when diagnosed. Venetoclax is an experimental drug that kills cancer cells by blocking a protein (part of a cell) that allows cancer cells to stay alive. This study is designed to see if adding venetoclax to azacitidine works better than azacitidine on its own. This is a Phase 3, randomized, double-blind (treatment is unknown to participants and doctors), placebo controlled study in patients with AML who are \>= 18 or more years old and have not been treated before. Participants who take part in this study should not be suitable for standard induction therapy (usual starting treatment). AbbVie is funding this study which will take place at approximately 180 hospitals globally and enroll approximately 400 participants. In this study, 2/3 of participants will receive venetoclax every day with azacitidine and the remaining 1/3 will receive placebo (dummy) tablets with azacitidine. Participants will continue to have study visits and receive treatment for as long as they are having a clinical benefit. The effect of the treatment on AML will be checked by taking blood, bone marrow, scans, measuring side effects and by completing health questionnaires. Blood and bone marrow tests will be completed to see why some people respond better than others. Additional blood tests will be completed for genetic factors and to see how long the drug remains in the body.
Primary Outcome
OS is defined as the number of days from the date of randomization to the date of death. Log rank test was used to compare the OS distribution between two treatment arms. Cox regression was used to report the hazard ratio.
Conditions Studied
Interventions
- DRUG Venetoclax
- DRUG Placebo
- DRUG Azacitidine
Study Locations (20)
California
- City of Hope /ID# 154105 - Duarte
- University of California, Los Angeles /ID# 154107 - Los Angeles
- University of California, Davis Comprehensive Cancer Center /ID# 162725 - Sacramento
Massachusetts
- Massachusetts General Hospital /ID# 200752 - Boston
- Beth Israel Deaconess Medical Center /ID# 201155 - Boston
- Dana-Farber Cancer Institute /ID# 167009 - Boston
Illinois
- Northwestern University Feinberg School of Medicine /ID# 201133 - Chicago
- University of Chicago Medicine /ID# 154108 - Chicago
New York
- Columbia Univ Medical Center /ID# 154101 - New York
- Memorial Sloan Kettering Cancer Center-Koch Center /ID# 165077 - New York
Georgia
- Emory Midtown Infectious Disease Clinic /ID# 162534 - Atlanta
Indiana
- Fort Wayne Medical Oncology /ID# 157190 - Fort Wayne
Kansas
- Cotton-O'Neil Clinical Res Ctr /ID# 155136 - Topeka
Kentucky
- Norton Cancer Institute /ID# 154992 - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 443 participants |
| Start Date | 2017-02-02 |
| Est. Completion | 2026-01-23 |
| Phase | Phase 3 |
What the registry record for NCT02993523 still lists
NCT02993523 is an interventional study that assigns participants to a tested intervention. The registered 443 participants enrollment target is mid-sized for trials with a published cap, above the 130-participant average among 29 other Acute Myeloid Leukemia (AML) trials with a reported enrollment target (241% higher).
The record links to 1 condition, with Acute Myeloid Leukemia (AML) appearing as the primary indexed condition, and to 3 interventions - of which Venetoclax is the first listed.
NCT02993523 names 20 study sites across 14 states, led by California, Massachusetts, Illinois.
Frequently Asked Questions
What is clinical trial NCT02993523 about?
NCT02993523 is a clinical study titled "A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy". Acute Myeloid Leukaemia (AML) is an aggressive and rare cancer of myeloid cells (a white blood cell responsible for fighting infections). Successful treatment of AML is dependent on what subtype of AML the participant has, and the age of the participant when diagnosed. Venetoclax is an experimental...
What is the current status of trial NCT02993523?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 443 participants. The study started on 2017-02-02. Estimated completion is 2026-01-23.
What conditions does trial NCT02993523 study?
This clinical trial studies the following conditions: Acute Myeloid Leukemia (AML).
What interventions are being tested in trial NCT02993523?
The interventions under investigation include: Venetoclax (DRUG), Placebo (DRUG), Azacitidine (DRUG).
Who is sponsoring clinical trial NCT02993523?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02993523 being conducted?
This trial has 20 study locations across California, Georgia, Illinois, Indiana, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myeloid Leukemia (AML)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02993523's enrollment target sits among peer trials
443 2nd of 29 the highest of 29 other Acute Myeloid Leukemia (AML) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acute Myeloid Leukemia (AML) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
RECRUITING · Phase 3
-
A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy
ACTIVE NOT RECRUITING · Phase 3
-
A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in Patients With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy
COMPLETED · Phase 3
-
Study of Elacytarabine Versus Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML)
COMPLETED · Phase 3
-
Ivosidenib as Post-HSCT Maintenance for AML
RECRUITING · Phase 2
-
A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06780670 · 443 participants · Phase 2
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
- NCT06348394 · 444 participants · NA
Intracardiac Versus Transesophageal Echocardiographic Guidance for Left Atrial Appendage Occlusion
- NCT06700343 · 444 participants · Phase 3
Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)
- NCT03704766 · 442 participants · NA
Alpha-Defensin and Synovial Proteins to Improve Detection of Pediatric Septic Arthritis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI